Adverse effects (drop‐outs due to adverse effects4) · patients with major depression
It is very uncertain whether agomelatine changes drop outs due to side effects Number of participants who dropped out… compared with SNRI (very low certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with major depression
It is very uncertain whether agomelatine changes total number of patients with side effects Total number of… compared with SNRI (very low certainty).
1 finding from 1 review
Remission · patients with major depression
It is very uncertain whether agomelatine changes remission rates The number of participants who achieved remission as… compared with SSRI (very low certainty).
1 finding from 1 review
Total drop outs Total number of participants who dropped out during the trial as a proportion of the total number of randomised participants · patients with major depression
It is very uncertain whether agomelatine changes total drop outs Total number of participants who dropped out during… compared with SSRI (very low certainty).
1 finding from 1 review
Drop out due to inefficacy Number of participants who dropped out due to inefficacy during the trial, as a proportion of the total number of randomised participants · patients with major depression
It is very uncertain whether agomelatine changes drop out due to inefficacy Number of participants who dropped out… compared with SSRI (very low certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with major depression
It is very uncertain whether agomelatine changes drop outs due to side effects Number of participants who dropped out… compared with SSRI (very low certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with major depression
It is very uncertain whether agomelatine changes total number of participants with side effects Total number of… compared with SSRI (very low certainty).
1 finding from 1 review
Response rates Number of participants showing a reduction of at least 50% on the Hamilton Depression Rating Scale for Depression, the Montgomery‐Asberg Depression Rating Scale or any other depression scale · patients with major depression
It is very uncertain whether agomelatine changes response rates Number of participants showing a reduction of at… compared with SNRI (very low certainty).
1 finding from 1 review
Remission · patients with major depression
It is very uncertain whether agomelatine changes remission rates The number of participants who achieved remission as… compared with SNRI (very low certainty).
1 finding from 1 review
Total drop outs Total number of participants who dropped out during the trial as a proportion of the total number of randomised participants · patients with major depression
It is very uncertain whether agomelatine changes total drop outs Total number of participants who dropped out during… compared with SNRI (very low certainty).
1 finding from 1 review
Depressive disorder according to DSM or ICD criteriaClinician diagnostic interview · patients with depressive disorders in children and adolescents
1 finding from 1 review
Suicide completionCompleted suicide rates · patients with depressive disorders in children and adolescents
1 finding from 1 review
Remission or response (as defined in trial) · patients with depressive disorders in children and adolescents
Second generation antidepressant probably leads to higher remission or response (as defined in trial) compared with placebo (by medication) (moderate certainty).
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with depressive disorders in children and adolescents
Second generation antidepressant may leads to higher suicide‐related outcome compared with placebo (by medication) (low certainty).
1 finding from 1 review
Depressive symptoms · patients with depressive disorders in children and adolescents
1 finding from 1 review
Outcomes3 · patients with adjustment disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Partial return to work · patients with adjustment disorders
1 finding from 1 review
Full return to work Scale from: ‐180 to +180 days · patients with adjustment disorders
1 finding from 1 review
Distress at · patients with adjustment disorders
1 finding from 1 review
Number relapsed‐recurred · patients with preventing relapse and recurrence of a depressive disorder in children and adolescents
Medication probably leads to lower number relapsed‐recurred compared with placebo (moderate certainty).
1 finding from 1 review